COMMUNIQUÉS West-GlobeNewswire

Prime Biome Reviews 2025: Updated Comprehensive Guide to the Revolutionary Gut & Skin Health Supplement!

22/04/2025 - 11:33

A 360° Look at Ingredients, Expert Insights, Real Results & User Feedback St. Petersburg, Florida, April 22, 2025 (GLOBE NEWSWIRE) -- Explore how PrimeBiome is transforming gut and skin health in 2025. This detailed [...]

PrimeBiome Reviews: “Gut–Skin Miracle” or Just Hype? Expert Insights

22/04/2025 - 11:42

St. Petersburg, Florida, April 22, 2025 (GLOBE NEWSWIRE) -- With over 19,000 customer reviews and rising buzz across wellness communities, Prime Biome is being hailed as a “gut–skin miracle”—but does it actually live up [...]

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

22/04/2025 - 12:00

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s [...]

AscellaHealth Demonstrates Leadership in Realizing the Full Potential of Novel Therapies and Medicinal Products at Advanced Therapies Integrates North 2025

22/04/2025 - 12:00

DUBLIN and BERWYN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customisable solutions to support the specialty pharmaceutical industry, proudly announces its participation in [...]

R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold

22/04/2025 - 12:00

MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial [...]

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

22/04/2025 - 12:45

MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company [...]

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

22/04/2025 - 12:55

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has [...]

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

22/04/2025 - 12:59

- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical [...]

EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting

22/04/2025 - 13:00

Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical [...]

PolyPid to Participate in The Citizens Life Sciences Conference

22/04/2025 - 13:00

PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s [...]

Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

22/04/2025 - 13:00

TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]

Rapport Therapeutics to Participate in Upcoming Investor Conferences

22/04/2025 - 13:00

BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

22/04/2025 - 13:00

Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses pacemaker-indicated [...]

Axsome Therapeutics to Participate in Upcoming Investor Conferences

22/04/2025 - 13:00

NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it [...]

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

22/04/2025 - 13:00

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. [...]

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

22/04/2025 - 13:00

ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

22/04/2025 - 13:00

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel [...]

Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference

22/04/2025 - 13:00

CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]

Transactions in Connection with Share Buy-back Program

22/04/2025 - 13:23

Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]